Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

2019 update to Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Circulating metabolites in progression to islet autoimmunity and type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  • John B Buse
  • Deborah J Wexler
  • Apostolos Tsapas
  • Peter Rossing
  • Geltrude Mingrone
  • Chantal Mathieu
  • David A D'Alessio
  • Melanie J Davies
View graph of relations

The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodium-glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1c target; (2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with CKD (eGFR 30 to ≤60 ml min-1 [1.73 m]-2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE and cardiovascular death.

Original languageEnglish
JournalDiabetologia
Volume63
Pages (from-to)221-228
ISSN0012-186X
DOIs
Publication statusPublished - Jan 2020

    Research areas

  • Cardiovascular disease, Chronic kidney disease, Glucose-lowering therapy, Guidelines, Heart failure, Hypoglycaemia, Patient-centred care, Type 2 diabetes mellitus

ID: 58665478